发布求助
文献互助 智能选刊 最新文献

Handbook of Research on Advancements in Cancer Therapeutics最新文献

筛选
英文 中文
Cancer Immunotherapy 癌症免疫疗法
Handbook of Research on Advancements in Cancer Therapeutics Pub Date : 1900-01-01 DOI: 10.4018/978-1-7998-6530-8.ch001
M. Hasan, B. S. Alotaibi, Sultan F. Alnomasy, K. U. Fakhri
{"title":"Cancer Immunotherapy","authors":"M. Hasan, B. S. Alotaibi, Sultan F. Alnomasy, K. U. Fakhri","doi":"10.4018/978-1-7998-6530-8.ch001","DOIUrl":"https://doi.org/10.4018/978-1-7998-6530-8.ch001","url":null,"abstract":"Cancer immunotherapy has become a powerful clinical strategy as well as an established pillar for the treatment of cancers to improving the prognosis of many cancer patients with a broad variety of solid tumors as well as blood cancers. The primary goals of immunotherapy are (a) to increase anti-tumor response, (b) decrease the immune suppression, and (c) to enhance the immunogenicity of tumors. This chapter aims to discuss the mechanism and different types of immunotherapies used for different cancers. It will also focus on recombinant products including immunostimulants, immunotoxins, antibodies, fusion proteins, engineered cytotoxic T cells, engineered immunocytokines, vaccines, checkpoint inhibitors, CAR T-cell therapy, and nanomedicine. Although immunotherapy has a rare side effect, it is not fully understood. The development of new strategies has been on the clinical trial to enhance the benefit of cancer patients to meet with challenges of limited efficacy and/or toxicity.","PeriodicalId":168608,"journal":{"name":"Handbook of Research on Advancements in Cancer Therapeutics","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117293240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutrition and Cancer 营养与癌症
Handbook of Research on Advancements in Cancer Therapeutics Pub Date : 1900-01-01 DOI: 10.4018/978-1-7998-6530-8.ch021
Shazia Ali, Asiya Batool, A. Tariq, A. Bhat, A. Qureshi, Basharat Bashir Teli, I. Qasim, Sumit Kumar, Abhilash Gangadharan, Raj Kumar, B. V. Prasad
{"title":"Nutrition and Cancer","authors":"Shazia Ali, Asiya Batool, A. Tariq, A. Bhat, A. Qureshi, Basharat Bashir Teli, I. Qasim, Sumit Kumar, Abhilash Gangadharan, Raj Kumar, B. V. Prasad","doi":"10.4018/978-1-7998-6530-8.ch021","DOIUrl":"https://doi.org/10.4018/978-1-7998-6530-8.ch021","url":null,"abstract":"Cancer is the second biggest killer worldwide. It has been estimated that specific lifestyle and dietary measures can prevent 30–40% of all cancers. Consumption of nutrient sparse foods, such as refined flour products and concentrated sugars, consumption of red meat, low fibre intake, and disproportion of omega 3 and omega 6 fatty acids, contributes to cancer risks. Microbiological and chemical food contaminants as well as conventional and industrial food processing methods may further increase the carcinogenicity of diets while protective agents in a cancer prevention diet include folic acid, selenium, vitamin D, vitamin B-12, chlorophyll, and antioxidants such as the carotenoids, kryptoxanthin, lycopene, and lutein. Diet can also influence the gut microbes that may have positive or adverse effects on cancer risk. The authors summarize cancer prevention by functional foods and discuss the role of different dietary factors such as promoter or inhibitor in pathogenesis of different subtypes of cancer worldwide.","PeriodicalId":168608,"journal":{"name":"Handbook of Research on Advancements in Cancer Therapeutics","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131314726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gene Therapy and Gene Editing for Cancer Therapeutics 癌症治疗的基因治疗和基因编辑
Handbook of Research on Advancements in Cancer Therapeutics Pub Date : 1900-01-01 DOI: 10.4018/978-1-7998-6530-8.ch004
Shubhjeet Mandal, P. Tiwari
{"title":"Gene Therapy and Gene Editing for Cancer Therapeutics","authors":"Shubhjeet Mandal, P. Tiwari","doi":"10.4018/978-1-7998-6530-8.ch004","DOIUrl":"https://doi.org/10.4018/978-1-7998-6530-8.ch004","url":null,"abstract":"Over the past two decades, developments in human genomics have shown that cancer in the host genome is caused by somatic aberration. This discovery has inspired interest among cancer researchers; many are now using genetic engineering therapeutic methods to improve the cancer regression and seeking a possible cure for the disease. The large gene therapy sector offers a variety of therapies which are likely to become effective in preventing cancer deaths. The latest clinical trials of third generation vaccines for a wide variety of cancers have produced promising results. Cancer virotherapy, which uses viral particles replicating within the cancer cell, is an emerging method of treatment which shows great promise. The latest developments in gene editing techniques, such as CRISPR, Cas9, TALENs, and ZFNs, are being used to help to make cancer a manageable condition. Gene therapy is expected to play a significant role in potential cancer therapy as a part of a multi-modality procedure.","PeriodicalId":168608,"journal":{"name":"Handbook of Research on Advancements in Cancer Therapeutics","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123037286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Receptor-Based Combinatorial Nanomedicines 基于受体的组合纳米药物
Handbook of Research on Advancements in Cancer Therapeutics Pub Date : 1900-01-01 DOI: 10.4018/978-1-7998-6530-8.CH011
H. Barkat, M. A. Barkat, M. Taleuzzaman, S. S. Das, M. Rizwanullah, H. Hadi
{"title":"Receptor-Based Combinatorial Nanomedicines","authors":"H. Barkat, M. A. Barkat, M. Taleuzzaman, S. S. Das, M. Rizwanullah, H. Hadi","doi":"10.4018/978-1-7998-6530-8.CH011","DOIUrl":"https://doi.org/10.4018/978-1-7998-6530-8.CH011","url":null,"abstract":"Nanotechnology-based drug-delivery systems, as an anticancer therapy tool, have shown significant potentials for the diagnosis and treatment of cancer. Recent studies have demonstrated that cancer therapy could be efficiently achieved by combinatorial therapies, approaches using multiple drug regimens for targeting cancers. However, their usages have been limited due to shorter half-lives of chemotherapeutic agents, insignificant targetability to tumor sites and suboptimal levels of co-administered conventional drug moieties. Thus, nanotechnology-based drug-delivery systems with effective targetability have played a crucial role to overcome the limitations and challenges associated with conventional therapies and also have provided greater therapeutic efficacy. Herein, the authors have focused on various drug-incorporated combinatorial nanocarrier systems, the significance of various receptors-associated strategies, and various targeted delivery approaches for chemotherapeutic agents.","PeriodicalId":168608,"journal":{"name":"Handbook of Research on Advancements in Cancer Therapeutics","volume":"82 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116786904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Advancements in Cancer Therapeutics 癌症治疗的进展
Handbook of Research on Advancements in Cancer Therapeutics Pub Date : 1900-01-01 DOI: 10.4018/978-1-7998-6530-8.ch003
Bilge Bicak, Serda Kecel Gunduz, Aysen E. Ozel
{"title":"Advancements in Cancer Therapeutics","authors":"Bilge Bicak, Serda Kecel Gunduz, Aysen E. Ozel","doi":"10.4018/978-1-7998-6530-8.ch003","DOIUrl":"https://doi.org/10.4018/978-1-7998-6530-8.ch003","url":null,"abstract":"Targeted drug delivery in cancer treatment is a very convenient method for increasing the effectiveness of drugs and reducing their toxic side effects. Nano drug delivery systems have unique physical, chemical, mechanical, and optical properties. Nanoparticles, which have large surface areas and functional groups for the binding of therapeutic agents, benefit the drug distribution with nanoparticle formulations and can provide new features. They also enable personal oncology for diagnosis and treatment, which is appropriate for the personal molecular profile structures of cancer patients. The tumor-targeted active substances are attached to nanoparticles and the active substance loaded nanoparticles are targeted to the tumor area; these nanoparticles can be used with a high tendency to bind and specificity, to target tumor antigens or vessels. This chapter, besides traditional chemotherapy and radiotherapy methods in the field of cancer treatment, is aimed to give information about targeted drug delivery systems for cancer cell targeting without damaging normal tissues.","PeriodicalId":168608,"journal":{"name":"Handbook of Research on Advancements in Cancer Therapeutics","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132787163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信